COMPASS Pathways (CMPS)
2.79
-0.07 (-2.45%)
At close: Apr 01, 2025, 3:59 PM
2.81
0.76%
After-hours: Apr 01, 2025, 07:56 PM EDT
Company Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States.
It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder.
The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways
| Country | GB |
| IPO Date | Sep 18, 2020 |
| Industry | Medical - Care Facilities |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Kabir Kumar Nath M.A., M.B.A. |
Contact Details
Address: 33 Broadwick Street London, GB | |
| Website | https://compasspathways.com |
Stock Details
| Ticker Symbol | CMPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001816590 |
| CUSIP Number | 20451W101 |
| ISIN Number | US20451W1018 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kabir Kumar Nath M.A., M.B.A. | Chief Executive Officer & Director |
| Anne Benedict | Chief People Officer |
| Dr. Greg Ryslik Ph.D. | Chief Technology Officer |
| Teri Loxam M.B.A. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Dr. Guy Goodwin | Chief Medical Officer |
| Dr. Michael Gold M.D., M.Sc. | Chief Research & Development Officer |
| Dr. Susan C. Stansfield Ph.D. | Advisor |
| Lars Christian Wilde | Senior Advisor |
| Lori Englebert M.B.A. | Chief Commercial Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2025 | 4 | Filing |
| Mar 13, 2025 | 4 | Filing |
| Mar 13, 2025 | 4 | Filing |
| Mar 05, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Mar 04, 2025 | 4 | Filing |
| Feb 27, 2025 | S-8 | Filing |
| Feb 27, 2025 | S-3 | Filing |
| Feb 27, 2025 | 8-K | Current Report |
| Feb 27, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |